Related references
Note: Only part of the references are listed.Cumulative pemetrexed dose increases the risk of nephrotoxicity
N. de Rouw et al.
LUNG CANCER (2020)
Modulating tumor immunity by metronomic dosing of oxaliplatin incorporated in multiple oral nanoemulsion
Jeong Uk Choi et al.
JOURNAL OF CONTROLLED RELEASE (2020)
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy
David A. Schaer et al.
CLINICAL CANCER RESEARCH (2019)
Intestinal transport mechanism and in vivo anticancer efficacy of a solid oral formulation incorporating an ion-pairing complex of pemetrexed with deoxycholic acid derivative
Rudra Pangeni et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2019)
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Junjie Wu et al.
CANCER LETTERS (2018)
Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect
Rudra Pangeni et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis
Xia Yuan et al.
GYNECOLOGIC ONCOLOGY (2017)
A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells
Irina Kareva
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study
Marina E. Cazzaniga et al.
TUMORI JOURNAL (2017)
Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study
Marina E. Cazzaniga et al.
TUMORI JOURNAL (2017)
Metronomic chemotherapy and immunotherapy in cancer treatment
Yu-Li Chen et al.
CANCER LETTERS (2017)
Low-dose metronomic chemotherapy with cisplatin enhanced immunity in a murine model of ectopic cervical cancer
Ching-Chou Tsai et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2016)
Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: preparation and in vivo evaluation
Rudra Pangeni et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2016)
Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells
Tze-Sian Chan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi et al.
CANCER CELL (2015)
Metronomic chemotherapy from rationale to clinical studies: A dream or reality?
Antonio Gnoni et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
Stanleyson V. Hato et al.
CLINICAL CANCER RESEARCH (2014)
Metronomic chemotherapy
Rituparna Maiti
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS (2014)
Profound Impairment of Adaptive Immune Responses by Alkylating Chemotherapy
Adam J. Litterman et al.
JOURNAL OF IMMUNOLOGY (2013)
Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
Lana E. Kandalaft et al.
ONCOIMMUNOLOGY (2013)
Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
Masataka Yoshimoto et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
Eva Ellebaek et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus
Vincenzo Cerullo et al.
MOLECULAR THERAPY (2011)
Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report
E. Munzone et al.
BREAST (2010)
Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor Angiogenesis
Chi-An Chen et al.
MOLECULAR THERAPY (2010)
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesniere et al.
ONCOGENE (2010)
Oxaliplatin-induced acute thrombocytopenia
Jessica M Mason et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2010)
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
Claire Banissi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Pemetrexed and oxaliplatin for metastatic colorectal cancer: Results of a phase I Mayo cancer center research consortium trial, MC0248
Steven R. Alberts et al.
CLINICAL COLORECTAL CANCER (2007)
Renal toxicity of Oxaliplatin
J Labaye et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2005)
Pemetrexed: A multitargeted antifolate
KD Rollins et al.
CLINICAL THERAPEUTICS (2005)
Review of a promising new agent - Pemetrexed disodium
L Paz-Ares et al.
CANCER (2003)
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism
GJ Peters et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2002)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)